NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 97.36.
Share Price | ₹13,397.2 | Sep 01,2025 |
Market Cap | ₹17,148.4 Cr | |
Earnings-TTM | ₹176.1 Cr | TTM-Consolidated Results |
Price/Earnings | 97.36x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹17,148.4 Cr] as on Sep 01,2025
(/) Earnings [ ₹176.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 97.36x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 97.36 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NEULAND LABORATORIES | 176.13 | 97.36 | 17,148.4 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 36.03 | 375,100.0 |
DIVIS LABORATORIES LTD | 2,306.00 | 70.12 | 161,698.0 |
CIPLA LTD | 5,406.81 | 23.72 | 128,239.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 60.55 | 121,216.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 18.66 | 106,855.0 |
MANKIND PHARMA LTD | 1,905.51 | 54.56 | 103,972.0 |
ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.49 | 99,682.6 |
LUPIN LTD | 3,722.18 | 23.30 | 86,717.1 |
AUROBINDO PHARMA LTD | 3,417.93 | 17.43 | 59,567.0 |
ABBOTT INDIA LTD | 1,452.29 | 46.93 | 68,151.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 17.43x |
Max industry PE | 97.36x |
Median industry PE | 36.03x |
Average industry PE | 42.74x |
You may also like the below Video Courses